Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Standardized Initial Therapy for Newly Diagnosed Pediatric UC (PROTECT)
NCT01536535Phase 4Completed
- Sponsor
- Connecticut Children's Medical Center
- Start
- Jul 2012
- Primary completion
- Apr 2018
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 4, open-label trial of Salcrozine and prednisone in ulcerative colitis (UC) (2 arms), sponsored by Connecticut Children's Medical Center. Primary endpoints: Number of Participants With Corticosteroid Free Remission (SFR) at 52 weeks and Number of Participants Who Needed Additional Therapy or Colectomy at 52 weeks. Started Jul 2012; status: completed.
02
Drugs
Salcrozineprednisone
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT01536535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01536535.